Bruker (NASDAQ:BRKR) Announces Earnings Results

Bruker (NASDAQ:BRKR) issued its quarterly earnings results on Wednesday. The medical research company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.14, FiscalAI reports. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The business had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. During the same quarter in the prior year, the business posted $0.45 earnings per share. The business’s quarterly revenue was up 1.6% on a year-over-year basis.

Here are the key takeaways from Bruker’s conference call:

• Margins and adjusted EPS improved sharply: Q3 non-GAAP operating margin rose 400 basis points to 16.3%, and diluted non-GAAP EPS increased 24% to $0.56, helped by cost savings and favorable product mix.
• Bookings point to improving demand: BSI book-to-bill remained above one for a fifth consecutive quarter, with year-to-date bookings and backlog up mid-single digits. Management cited strong China demand, a return to U.S. academic and government bookings growth, and more than 30% year-to-date growth in semiconductor metrology orders.
• Bruker reaffirmed its 2026 organic revenue growth outlook of 1%–2% and non-GAAP EPS range of $2.10–$2.15; it expects lower-mid-single-digit organic revenue growth in Q4. Management said 2027 should bring faster organic growth, further margin expansion, and double-digit EPS growth, while noting detailed guidance will come in February.
• Reported growth remained modest: Q3 organic revenue increased just 0.7%, while BSI organic revenue declined 0.4%, partly due to previously disclosed semiconductor instrument pushouts. GAAP results included a roughly $175 million non-cash goodwill impairment tied to Bruker Spatial Biology and a diluted loss per share of $0.81.

Bruker Price Performance

Shares of Bruker stock traded up $6.20 on Wednesday, hitting $62.70. 4,671,929 shares of the company traded hands, compared to its average volume of 2,365,464. Bruker has a 52 week low of $32.37 and a 52 week high of $68.98. The business has a 50-day simple moving average of $58.81 and a 200 day simple moving average of $50.41. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The stock has a market capitalization of $9.55 billion, a P/E ratio of -89.81, a price-to-earnings-growth ratio of 1.70 and a beta of 1.26.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were given a dividend of $0.05 per share. The ex-dividend date was Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is presently -28.57%.

Analyst Ratings Changes

BRKR has been the subject of several analyst reports. Guggenheim increased their target price on shares of Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. JPMorgan Chase & Co. cut shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research note on Wednesday, October 14th. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research report on Wednesday, August 5th. Finally, Citigroup lowered their target price on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.43.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 27.20% of the company’s stock.

Key Stories Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported third-quarter earnings of $0.56 per share, above the $0.42 consensus estimate and up from $0.45 a year earlier. Revenue of $874 million also exceeded expectations of $865.16 million, with sales rising 1.6% year over year. The earnings and revenue beats are the clearest near-term catalysts for the shares. Read article
• Positive Sentiment: Bruker said U.S. academic-market demand returned in Q3 and is targeting double-digit EPS growth in fiscal 2027, suggesting a potential improvement in a market that had been an overhang. Read article
• Neutral Sentiment: For 2026, Bruker forecast revenue of $3.52 billion to $3.56 billion, putting the midpoint slightly below FactSet’s $3.56 billion estimate. Its non-GAAP EPS outlook of $2.10 to $2.15 brackets the $2.12 consensus, broadly aligning with expectations. Read article
• Negative Sentiment: A report highlighted a steep goodwill charge despite improved margins, raising a potential concern about reported results and earnings quality. Read article

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.